NYSE:DVA DaVita (DVA) Stock Price, News & Analysis $181.36 -1.65 (-0.90%) Closing price 09/10/2026 03:59 PM EasternExtended Trading$181.32 -0.04 (-0.02%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DaVita Stock (NYSE:DVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DaVita alerts:Sign Up Key Stats Today's Range$180.47▼$184.4150-Day Range$174.21▼$240.5952-Week Range$101.00▼$247.49Volume565,244 shsAverage Volume553,436 shsMarket Capitalization$11.57 billionP/E Ratio14.84Dividend YieldN/APrice Target$233.43Consensus RatingModerate Buy Company Overview DaVita Inc. (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease. DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation. The company operates dialysis centers and related care programs primarily in the United States, with additional operations in selected international markets. The company traces its history to 1979, when it was established as Medical Ambulatory Care, and adopted the DaVita name in 2000. Javier Rodriguez serves as DaVita’s chief executive officer. The company’s operations are centered on its kidney-care platform and its network of clinicians, physicians and other healthcare professionals.AI Generated. May Contain Errors. Read More DaVita Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreDVA MarketRank™: DaVita scored higher than 93% of companies evaluated by MarketBeat, and ranked 8th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDaVita has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialDaVita has a consensus price target of $233.43, representing about 28.7% upside from its current price of $181.36.Amount of Analyst CoverageDaVita has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DaVita's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth18.39% Earnings GrowthEarnings for DaVita are expected to grow by 18.39% in the coming year, from $14.57 to $17.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DaVita is 14.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of DaVita is 14.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.82.Price to Earnings Growth RatioDaVita has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.Read more about DaVita's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.47% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 8.21.Change versus previous monthShort interest in DaVita has recently increased by 16.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaVita does not currently pay a dividend.Dividend GrowthDaVita does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.88 News SentimentDaVita has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for DaVita this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DaVita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,210,402.00 in company stock.Percentage Held by Insiders1.90% of the stock of DaVita is held by insiders.Percentage Held by Institutions90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DaVita's insider trading history. Receive DVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DVA Stock News HeadlinesTen healthcare stocks with A-rated valuations and strong revenue growthSeptember 9 at 6:49 PM | seekingalpha.comHealthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinksSeptember 5, 2026 | msn.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)DaVita reaches preliminary settlement class agreement following ransomware attackSeptember 4, 2026 | msn.comDaVita (DVA) Has Investors Asking A Fresh QuestionSeptember 4, 2026 | finance.yahoo.comAlebund Pharmaceuticals Announces 2026 Interim ResultsAugust 26, 2026 | prnewswire.comDaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney DiseaseAugust 25, 2026 | prnewswire.comDaVita (DVA) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | finance.yahoo.comSee More Headlines DVA Stock Analysis - Frequently Asked Questions How have DVA shares performed this year? DaVita's stock was trading at $113.74 on January 1st, 2026. Since then, DVA shares have increased by 59.5% and is now trading at $181.3620. How were DaVita's earnings last quarter? DaVita Inc. (NYSE:DVA) released its quarterly earnings data on Tuesday, August, 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The company's revenue for the quarter was up 5.2% on a year-over-year basis. Read the conference call transcript. Does DaVita have any subsidiaries? DaVita subsidiaries include Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others. Who are DaVita's major shareholders? DaVita's top institutional shareholders include Berkshire Hathaway Inc (45.27%), California State Teachers Retirement System (13.50%), BlackRock Inc. (3.86%) and Bank of America Corp DE (1.02%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty and Barbara J Desoer. View institutional ownership trends. How do I buy shares of DaVita? Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DaVita own? Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/04/2026Today9/10/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DVA's financial health is in the Red zone, according to TradeSmith. DVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DVA CIK927066 Webwww.davita.com Phone(310) 536-2668Fax302-636-5454Employees78,000Year Founded1994Price Target and Rating Average Price Target for DaVita$233.43 High Price Target$270.00 Low Price Target$215.00 Potential Upside/Downside+28.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$12.22 Trailing P/E Ratio14.84 Forward P/E Ratio12.45 P/E Growth0.47Net Income$746.80 million Net Margins6.05% Pretax Margin10.48% Return on Equity-217.63% Return on Assets5.07% Debt Debt-to-Equity RatioN/A Current Ratio1.47 Quick Ratio1.41 Sales & Book Value Annual Sales$13.64 billion Price / Sales0.85 Cash Flow$21.51 per share Price / Cash Flow8.43 Book Value($5.29) per share Price / Book-34.28Miscellaneous Outstanding Shares63,800,000Free Float62,588,000Market Cap$11.57 billion OptionableOptionable Beta0.83 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:DVA) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DaVita Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DaVita With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
